within Pharmacolibrary.Drugs.ATC.R;

model R02AD05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 66 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ambroxol is a mucolytic agent used to facilitate the clearance of mucus from the respiratory tract. It is commonly prescribed to treat acute and chronic diseases of the respiratory tract associated with viscid or excessive mucus. Ambroxol is widely approved and used in clinical practice, especially in Europe and Asia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Yang, YG, et al., &amp; Zhang, M (2015). Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers. <i>International journal of clinical and experimental medicine</i> 8(10) 18744–18750. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26770490/&quot;>https://pubmed.ncbi.nlm.nih.gov/26770490</a></p></li><li><p>Jiang, B, et al., &amp; Ruan, ZR (2014). Pharmacokinetics and bioequivalence study of three oral formulations of ambroxol 30 mg: a randomized, three-period crossover comparison in healthy volunteers. <i>International journal of clinical pharmacology and therapeutics</i> 52(10) 920–926. DOI:<a href=&quot;https://doi.org/10.5414/CP202156&quot;>10.5414/CP202156</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25207547/&quot;>https://pubmed.ncbi.nlm.nih.gov/25207547</a></p></li><li><p>Wang, Y, et al., &amp; Ding, L (2018). Pharmacokinetics and safety of salbutamol/ambroxol fixed-dose combination granules in healthy Chinese subjects . <i>International journal of clinical pharmacology and therapeutics</i> 56(12) 597–603. DOI:<a href=&quot;https://doi.org/10.5414/CP203212&quot;>10.5414/CP203212</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30232958/&quot;>https://pubmed.ncbi.nlm.nih.gov/30232958</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R02AD05;
